Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | RAF1 | P04049 | 8/20 | 0.72 |
| ▸ | BRAF | P15056 | 8/20 | 0.72 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | FLT1 | P17948 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.65 |
| ▸ | KIF5B | P33176 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15077870 | 0.90 | RAF1 (0.84) | HTTMAPK1KDM4ERAF1BRAF | |
| SCHEMBL9215676 | 0.89 | EGFR (0.74) | HTTMAPK1KDM4ERAF1BRAF | |
| SCHEMBL8871863 | 0.89 | EGFR (0.82) | HTTMAPK1KDM4EMAPTHPGD | |
| SCHEMBL15077994 | 0.85 | RAF1 (0.74) | HTTMAPK1KDM4ERAF1BRAF | |
| SCHEMBL3682274 | 0.85 | FGFR1 (0.70) | HTTRAF1BRAFGLAEGFR | |
| SCHEMBL2101381 | 0.84 | HTT (1.00) | HTTMAPK1KDM4ERAF1BRAF | |
| SCHEMBL15051952 | 0.84 | BRAF (1.00) | HTTMAPK1RAF1BRAFGLA | |
| SCHEMBL18292535 | 0.84 | RAF1 (0.72) | HTTRAF1BRAFGLAEGFR | |
| SCHEMBL5564456 | 0.84 | MAPK1 (0.82) | HTTMAPK1KDM4EMAPTEGFR | |
| SCHEMBL5565226 | 0.84 | HTT (0.72) | HTTMAPK1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-0748219-B8 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-0748219-B1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | disclosed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5849742-A | Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis | SUGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5792771-A | FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5763441-A | ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS | SUGEN, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5712395-A | BENZO(G)QUINOXALINE | YISSUM RESEARCH DEVELOPMENT CORP. (IL) | 1998-01-27 | — | — | US | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | HTT 2700/4885MAPK1 1019/4885KDM4E 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.